Cargando…
Serglycin: At the Crossroad of Inflammation and Malignancy
Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth fac...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888995/ https://www.ncbi.nlm.nih.gov/pubmed/24455486 http://dx.doi.org/10.3389/fonc.2013.00327 |
_version_ | 1782299139933995008 |
---|---|
author | Korpetinou, Angeliki Skandalis, Spyros S. Labropoulou, Vassiliki T. Smirlaki, Gianna Noulas, Argyrios Karamanos, Nikos K. Theocharis, Achilleas D. |
author_facet | Korpetinou, Angeliki Skandalis, Spyros S. Labropoulou, Vassiliki T. Smirlaki, Gianna Noulas, Argyrios Karamanos, Nikos K. Theocharis, Achilleas D. |
author_sort | Korpetinou, Angeliki |
collection | PubMed |
description | Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the granules and their protection since they are secreted as complexes and delivered to their targets after secretion. During the last decade, numerous studies have demonstrated that serglycin is also synthesized by various non-hematopoietic cell types. It has been shown that serglycin is highly expressed by tumor cells and promotes their aggressive phenotype and confers resistance against drugs and complement system attack. Apart from its direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the tumor cell microenvironment thus enhancing tumor development. In the present review, we discuss the role of serglycin in inflammation and tumor progression. |
format | Online Article Text |
id | pubmed-3888995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-38889952014-01-22 Serglycin: At the Crossroad of Inflammation and Malignancy Korpetinou, Angeliki Skandalis, Spyros S. Labropoulou, Vassiliki T. Smirlaki, Gianna Noulas, Argyrios Karamanos, Nikos K. Theocharis, Achilleas D. Front Oncol Oncology Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the granules and their protection since they are secreted as complexes and delivered to their targets after secretion. During the last decade, numerous studies have demonstrated that serglycin is also synthesized by various non-hematopoietic cell types. It has been shown that serglycin is highly expressed by tumor cells and promotes their aggressive phenotype and confers resistance against drugs and complement system attack. Apart from its direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the tumor cell microenvironment thus enhancing tumor development. In the present review, we discuss the role of serglycin in inflammation and tumor progression. Frontiers Media S.A. 2014-01-13 /pmc/articles/PMC3888995/ /pubmed/24455486 http://dx.doi.org/10.3389/fonc.2013.00327 Text en Copyright © 2014 Korpetinou, Skandalis, Labropoulou, Smirlaki, Noulas, Karamanos and Theocharis. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Korpetinou, Angeliki Skandalis, Spyros S. Labropoulou, Vassiliki T. Smirlaki, Gianna Noulas, Argyrios Karamanos, Nikos K. Theocharis, Achilleas D. Serglycin: At the Crossroad of Inflammation and Malignancy |
title | Serglycin: At the Crossroad of Inflammation and Malignancy |
title_full | Serglycin: At the Crossroad of Inflammation and Malignancy |
title_fullStr | Serglycin: At the Crossroad of Inflammation and Malignancy |
title_full_unstemmed | Serglycin: At the Crossroad of Inflammation and Malignancy |
title_short | Serglycin: At the Crossroad of Inflammation and Malignancy |
title_sort | serglycin: at the crossroad of inflammation and malignancy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888995/ https://www.ncbi.nlm.nih.gov/pubmed/24455486 http://dx.doi.org/10.3389/fonc.2013.00327 |
work_keys_str_mv | AT korpetinouangeliki serglycinatthecrossroadofinflammationandmalignancy AT skandalisspyross serglycinatthecrossroadofinflammationandmalignancy AT labropoulouvassilikit serglycinatthecrossroadofinflammationandmalignancy AT smirlakigianna serglycinatthecrossroadofinflammationandmalignancy AT noulasargyrios serglycinatthecrossroadofinflammationandmalignancy AT karamanosnikosk serglycinatthecrossroadofinflammationandmalignancy AT theocharisachilleasd serglycinatthecrossroadofinflammationandmalignancy |